Dear NCCN Acute Myeloid Leukemia Panel:

On behalf of Celgene Corporation, we respectfully request that the NCCN Guidelines Panel for Acute Myeloid Leukemia (AML) review the enclosed information regarding the clinical importance of isocitrate dehydrogenase (IDH) testing for AML patients.

**Specific Changes:** Update the discussion section (pages MS-3 to MS-12) to include additional data supporting the prognostic impact of IDH mutations in AML patients. In addition, we request an update to the footnotes on pages AML-10 (**eef**) and AML-14 (**www**) to include molecular profiling of IDH mutations as it may assist with the selection of appropriate clinical trials.

**Rationale:** As stated in the current AML NCCN Guidelines, Version 2.2016, the evaluation of several molecular markers may be important for risk assessment and prognostication, and may also guide treatment decisions (MS-3). The recently published 2016 Revision to the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia has included IDH1 and IDH2 into the supplemental table for molecular genetic alterations affecting clinical outcome of AML patients in specific cytogenetic groups.1-2,6,8

Additionally, there are several ongoing clinical trials exploring the use of novel agents for AML patients harboring IDH mutations further underscoring the importance of molecular profiling to guide clinical trial selection. Information pertaining to ongoing clinical trials can be accessed on www.clinicaltrials.gov and via the following hyperlinks: NCT02632708, NCT02074839, NCT02719574, NCT02492737, NCT02677922, NCT02283190, NCT01915498, NCT02381886, NCT02577406.

The 2016 Revision to the WHO Classification of Myeloid Neoplasms and Acute Leukemia as well as the following articles evaluating the impact of IDH mutations in AML in support of these proposed changes are enclosed for your review.2-12 Several studies have demonstrated poorer outcomes in patients with mutant IDH compared to patients without IDH mutations.2,4,6-7,10-11 Your consideration of this submission is greatly appreciated.
References:


Sincerely,

Kiitan Babalola, PharmD
Manager, Global Medical Information

Mary Sugrue, MD, PhD
Executive Director, US Medical Affairs Disease Lead-MDS, AML